Our phase Ib clinical trial for the cotreatment with IN10018 and PLD exhibited long-lasting antitumor effects when comparing historical data regarding treatment with PLD alone in platinum-resistant ovarian cancer. This evidence concerns the gene GPLD1 and ovarian carcinoma.